Type 2 Diabetes

The Tulane Chief of Endocrinology recalls Dr. Frederick Banting's historic discovery in 1921, and how it still impacts diabetes care today.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

While drivers of gestational diabetes are not fully evidenced, data shows how it's linked to great likelihood of type 2 diabetes and cardiovascular events.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

A 3-year study with more than 500 patients, results suggest none of the study participants had a BCVA worse than 0.3 (log MAR 0.48) due to diabetic retinopathy.

The FDA and FTC posted warnings to 10 companies for violating the Federal Food, Drug, and Cosmetic Act by selling dietary supplements claiming to cure, treat, mitigate, or prevent diabetes.

Mean age of diabetes diagnosis was 4 - 7 years earlier among non-Hispanic Black and Mexican American adults, in comparison to non-Hispanic White adults.

New data describes risk factors associated with increased prevalence of sexual dysfunction among patients with type 1 and type 2 diabetes.

Editorial advisory board member Dr. Paul Thompson reflects on how advances in diabetes management have impacted cardiovascular medicine and why staying abreast of these advances is essential to being a cardiologist in 2021.

Investigators noted a need for multidisciplinary interventions for prevention of diabetic ketoacidosis and hyperglycemic hyperosmolar state in patients with diabetes.

Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.

Bertram Pitt, MD, offers perspective on how he interprets data from both FIDELIO-DKD and FIGARO-DKD inform the use of finerenone in patients with diabetes and chronic kidney disease.

Results of a post hoc analysis of the TWILIGHT trial provide insight into the effects of ticagrelor monotherapy compared to dual therapy with aspirin in patients with concomitant CKD and diabetes.

Results of FIGARO-DKD were presented at ESC Congress 2021 and, combined with FIDELIO-DKD data, demonstrate the ability of finerenone to provide benefit across the spectrum of eGFR.

Sexual dysfunction in men was related to clinical factors, including erectile dysfunction, while women reported low emotional well-being and symptoms of anxiety.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Deepak Bhatt, MD, discusses a presentation he gave at ESC Congress 2021 on SGLT2, 1/2 inhibition and reflects on the potential for sotagliflozin to receive approval from the FDA based on data from SOLOIST-WHF and SCORED.